An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Veliparib (Primary) ; Capecitabine
- Indications Rectal cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 11 May 2015 Final results will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), according to an Abbvie media release.
- 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.